Experienced in Nocardiosis

Dr. Francisco M. Marty

Infectious Disease
75 Francis St, Pbb A4 Brigham And Womens Hosp Dept Of Infectious Disea, 
Boston, MA 
Experienced in Nocardiosis
75 Francis St, Pbb A4 Brigham And Womens Hosp Dept Of Infectious Disea, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Francisco Marty is an Infectious Disease provider in Boston, Massachusetts. Dr. Marty is rated as an Experienced provider by MediFind in the treatment of Nocardiosis. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Sepsis, and Febrile Neutropenia.

His clinical research consists of co-authoring 173 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

75 Francis St, Pbb A4 Brigham And Womens Hosp Dept Of Infectious Disea, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Diagnostic test, Other
A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction
A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction
Enrollment Status: Completed
Publish Date: March 08, 2023
Intervention Type: Drug
Study Drug: Letermovir
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 6 Less Clinical Trials

173 Total Publications

Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.
Journal: Open forum infectious diseases
Published: January 26, 2023
Similar Doctors
Advanced in Nocardiosis
Dr. Robert A. Duncan
Infectious Disease
Advanced in Nocardiosis
Dr. Robert A. Duncan
Infectious Disease
Lahey Clinic, 41 Mall Road, 
Burlington, MA 
 (11.4 miles away)
781-744-8608
Languages Spoken:
English

Robert Duncan is an Infectious Disease provider in Burlington, Massachusetts. Dr. Duncan is rated as an Advanced provider by MediFind in the treatment of Nocardiosis. His top areas of expertise are Nocardiosis, Nontuberculous Mycobacterial Lung Disease, Lymphangitis, and Lyme Disease.

Advanced in Nocardiosis
Dr. Rocio M. Hurtado
Infectious Disease
Advanced in Nocardiosis
Dr. Rocio M. Hurtado
Infectious Disease

Massachusetts General Physicians Organization Inc

243 Charles St, Suite 1107, 
Boston, MA 
 (2.6 miles away)
617-273-5699
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rocio Hurtado is an Infectious Disease provider in Boston, Massachusetts. Dr. Hurtado is rated as an Advanced provider by MediFind in the treatment of Nocardiosis. Her top areas of expertise are Nontuberculous Mycobacterial Lung Disease, Nocardiosis, Mycobacterium Avium Complex Infections, Pneumocystis Jiroveci Pneumonia, and Orchiectomy. Dr. Hurtado is currently accepting new patients.

Advanced in Nocardiosis
Dr. Simran Gupta
Infectious Disease
Advanced in Nocardiosis
Dr. Simran Gupta
Infectious Disease
62 13th St, Suite 102, 
Charlestown, MA 
 (3.8 miles away)
Languages Spoken:
English
See accepted insurances

Simran Gupta is an Infectious Disease provider in Charlestown, Massachusetts. Dr. Gupta is rated as an Advanced provider by MediFind in the treatment of Nocardiosis. Her top areas of expertise are Coccidioidomycosis, Nocardiosis, Sepsis, and COVID-19.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marty's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile